A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC

Clinical trial NCT06745323 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06745323
Sponsor: Amgen
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Small Cell Lung Cancer (SCLC)

Start date: 2025-02-26
Primary completion: 2029-05-10
Enrollment: 252

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.